INCY Chart

1 Month

	Date	Diff
	2025-04-23	+1.08 %
Incyte (INCY) stock rose by 1.08% despite analysts from JPMorgan Chase lowering its price target from $70 to $68, demonstrating potential upside driven by investor interest despite mixed analyst ratings and recent insider sales. Incyte Co. (NASDAQ: INCY) stock rose by 1.08% due to a generally stable consensus rating of "Hold" from analysts, along with mixed recent price target adjustments from various research firms, indicating a cautiously optimistic outlook amid recent insider sales and institutional investment activity.
	2025-04-22	+1.02 %
Incyte (INCY) stock rose by 1.02% due to positive comparisons made by analysts between MacroGenics and Ensysce Biosciences, highlighting MacroGenics' favorable outlook, which may bolster investor confidence in related stocks in the biopharmaceutical sector.
	2025-04-11	+3.08 %
Incyte (INCY) stock rose by 3.08% last night due to positive overall market conditions driven by a pause on U.S. tariffs, which improved global sentiment and economic outlook, boosting investor confidence across various sectors.
	2025-04-08	-5.51 %
Incyte (INCY) stock fell by 5.51% likely due to investor concerns following the negative performance indicators and comparison to more established companies like Eli Lilly, which is perceived to have stronger financials and higher potential upside based on analyst recommendations.
	2025-04-07	-0.48 %
Incyte Corporation's stock (INCY) experienced a decline of 0.48% amid a backdrop of increased institutional investment, insider selling, and mixed analyst ratings, highlighting a possible lack of investor confidence and concerns over recent earnings performance.
	2025-03-25	-1.11 %
Incyte (NASDAQ:INCY) stock declined by 1.11% amidst a backdrop of mixed analyst ratings and notable insider selling, indicating potential investor uncertainty and profit-taking.
	2025-03-21	+2.21 %
Incyte (INCY) stock rose by 2.21% following an increase in earnings per share (EPS) estimates for FY2025 by analysts at William Blair, who now project earnings of $4.21 per share, slightly higher than previous estimates, despite a recent quarterly earnings miss. Incyte (INCY) stock rose by 2.21% last night despite recent declines due to less favorable news from a clinical trial, possibly indicating a rebound or renewed investor interest despite previous concerns.
	2025-03-20	+0.4 %
Incyte (INCY) stock increased by 0.4% despite being downgraded by William Blair from "outperform" to "market perform," likely due to other brokerages raising their price targets and maintaining hold or equal weight ratings, which may have instilled confidence among investors.
	2025-03-19	+0.57 %
HUTCHMED and Innovent announced successful results from the FRUSICA-2 Phase II/III clinical trial concerning a combination treatment for advanced renal cell carcinoma, which may have contributed to a 0.57% increase in Incyte (INCY) stock due to positive investor sentiment surrounding the efficacy of this new therapy. Incyte (INCY) stock rose by 0.57% following a series of analyst rating adjustments, including Guggenheim's downgrade to neutral, but with a maintained price target of $92, suggesting mixed investor sentiment about the stock's potential. The rise in stock price could be attributed to potential investor optimism and interest despite the recent downgrades, as well as strategic insider trading and the overall market dynamics for healthcare stocks. Incyte (INCY) stock rose by 0.57% despite a reduction in its price target by Truist Financial from $74.00 to $72.00 and several downgrades from other analysts, indicating potential modest investor optimism or confidence amidst the mixed ratings.
	2025-03-17	-8.62 %
Incyte (INCY) stock dropped more than 10% after the company reported disappointing clinical trial results for its oral treatment for hidradenitis suppurativa (HS). Incyte (INCY) stock fell by 8.62% due to an analyst's assessment that its skin disease treatment, while viable, is not competitive with existing biologic therapies. Incyte Corporation's stock (NASDAQ: INCY) dropped by 8.62% following the release of topline results from its pivotal Phase 3 STOP-HS clinical trial for povorcitinib, which may not have met investor expectations or demonstrated sufficient efficacy or safety.
	2025-03-11	-4.3 %
The article discusses the positive results of a study on Incyte Corporation's drug baricitinib for treating adolescent patients with severe alopecia areata, yet Incyte’s stock fell by 4.3%. The decline in Incyte (INCY) stock may be attributed to overall market conditions or investor sentiment, which often reacts to broader factors beyond just the study results, such as profit-taking or concerns about future sales performance.
	2025-03-10	+0.48 %
The article compares Cortexyme (CRTX) and Agenus (AGEN) as investment options, noting that Cortexyme has higher earnings but lower revenue, and also highlights institutional ownership as a positive indicator for both stocks, with Agenus having a stronger consensus rating among analysts. Incyte (INCY) stock likely went up due to positive sentiment and strength in institutional ownership and earnings reports in the biotechnology sector.
	2025-03-07	+1 %
Incyte Co. (NASDAQ:INCY) experienced a 1.0% increase in stock price, attributed to a consensus "Hold" recommendation from brokerages and price target adjustments by analysts, indicating a stable outlook despite recent insider selling and negative earnings report.
	2025-03-03	-4.41 %
Syndax Pharmaceuticals recently reported a net loss for the fourth quarter of 2024, which included rising costs and ongoing financial losses, possibly contributing to a decline of 4.41% in Incyte (INCY) stock due to investor concerns about increased expenses and future profitability uncertainties.
	2025-02-20	+1.74 %
Incyte Corporation (INCY) stock rose 1.74% likely due to recent analyst upgrades, increased institutional investment activity, and the company's ongoing developments in its biopharmaceutical offerings, despite reporting earnings below analysts' expectations.
	2025-02-19	-1.56 %
Incyte Co. (NASDAQ: INCY) experienced a 1.56% decline in its stock price, primarily due to disappointing quarterly earnings that fell short of analyst expectations, which may have raised concerns among investors.
	2025-02-18	+1.21 %
Incyte (INCY) stock rose by 1.21% following a series of institutional investment changes and a positive outlook from analysts despite recent mixed earnings results, suggesting strong institutional support and confidence in future performance. Incyte Co. (NASDAQ: INCY) experienced a 1.21% increase in stock value, attributed to positive adjustments by institutional investors and favorable analyst ratings, including a raise from Bank of America to a "buy" rating with an increased price target from $68 to $90.
	2025-02-14	+0.59 %
Incyte (INCY) stock rose 0.59% due to a combination of institutional investors adjusting their stakes, notably increased holdings from hedge funds like CWM LLC, and positive analyst revisions of price targets, indicating a generally optimistic outlook despite recent earnings misses.
	2025-02-13	+1.39 %
Incyte (INCY) stock rose by 1.39% following an upgrade by Stifel Nicolaus from $75.00 to $77.00, along with several other positive adjustments in target prices and ratings from different brokerages.
	2025-02-12	+4.1 %
Incyte (INCY) stock rose 4.1% following analysts' upgrades, including a notable increase in target prices and ratings by various equity firms, despite a recent earnings miss. The stock's increase is largely attributed to positive adjustments in target prices and ratings from analysts, suggesting renewed confidence in the company's prospects. Incyte Corporation's stock (NASDAQ: INCY) experienced a 4.1% increase despite a recent 8.5% decline due to disappointing earnings, as research analysts have issued positive ratings and raised price targets, indicating potential for recovery. The stock may have gone up due to analysts' upgrades and positive forecasts which can enhance investor confidence despite the disappointing earnings report.
	2025-02-10	-7.86 %
Incyte (INCY) stock fell 7.9% due to the company reporting weaker-than-expected profits for the latest quarter compared to analysts' predictions. Incyte (INCY) stock dropped 7.86% due to broader market declines driven by concerns over US tariffs on steel and aluminum imports, which have heightened fears of global trade tensions impacting various sectors. Incyte Co. (INCY) shares fell by 7.86% after abrdn plc reported a 14.8% decrease in its holdings and a mixed outlook from various analysts, indicating potential concerns over the company's performance and valuation in the biopharmaceutical market. Incyte Corporation's stock (NASDAQ: INCY) dropped by 7.86%, following insider selling and a mixed evaluation from analysts, with an average recommendation of "Hold" among twenty ratings firms covering the stock. The decline in Incyte's stock is attributed to recent insider selling and the uncertainty reflected in analysts' ratings, which indicate caution among investors. Incyte (INCY) stock has declined by 7.86% as of last night, likely due to insider selling activity and mixed analyst ratings, despite increased institutional investment.
	2025-02-07	-1.09 %
Incyte Corporation's stock (NASDAQ:INCY) experienced a decline of 1.09% attributed to insider selling activity, as executives offloaded significant shares, leading to concerns about company confidence and potential market reaction.
	2025-02-06	-0.41 %
Incyte (INCY) stock experienced a decline of 0.41% despite being upgraded to a "strong-buy" rating by StockNews.com, due to mixed analyst opinions, insider selling, and fluctuations in market sentiment. The stock may have been affected negatively by the insider transactions and the overall cautious market atmosphere, even amidst positive analyst ratings and increased target prices for the stock. Incyte Corporation's stock (INCY) declined by 0.41%, attributed to insider selling and concentrated institutional ownership, with increasing concerns from some analysts regarding the stock's performance as reflected in the generally "hold" ratings from multiple research firms.
	2025-02-05	+1.54 %
Incyte (INCY) stock rose by 1.54% following increased institutional investment and positive ratings upgrades from several research firms, indicating growing confidence in the company's future prospects and stability in the biopharmaceutical sector. Incyte (NASDAQ: INCY) stock rose by 1.54% due to increased institutional investment, with Tokio Marine Asset Management Co. Ltd. and other investors boosting their holdings in the biopharmaceutical company during the fourth quarter.
	2025-02-04	+0.52 %
The article compares two small-cap medical companies, Innate Pharma and Agenus, highlighting Innate Pharma's stronger earnings, higher analyst ratings, and potential for greater stock price appreciation, which may help explain the recent 0.52% increase in Incyte’s stock price as investors are likely viewing it more favorably compared to its peers given favorable ratings and growth prospects. Incyte Co. (NASDAQ:INCY) stock rose by 0.52% following significant investment activity from institutional investors, including large purchases and repositioning by hedge funds, which reflects growing confidence in the company's biopharmaceutical developments and potential for future growth.
	2025-01-24	+0.08 %
Incyte Co. (NASDAQ: INCY) experienced a slight increase of 0.08% in its stock price, despite analysts revising their FY2024 earnings estimates downwards due to mixed performance and varied target price adjustments from multiple research firms; the stock's rise can be attributed to positive sentiment around its strong revenue growth and sustained interest from institutional investors.
	2025-01-23	+0.17 %
Incyte (INCY) stock rose 0.17% following a mixed sentiment from analysts; despite a lowered earnings estimate by William Blair, other firms have upgraded their ratings and targets, indicating a generally positive outlook for the company's performance and growth potential. Incyte Co. (NASDAQ: INCY) stock increased by 0.17% after several hedge funds and institutional investors acquired new stakes in the company, indicating positive investor sentiment and interest in its market potential.
	2025-01-17	-0.75 %
Incyte (INCY) stock experienced a decline of 0.75% amid news of various institutional investors, including the Czech National Bank, increasing their holdings in the company, despite it missing earnings estimates in its last quarterly report. The decrease in the stock price may be attributed to concerns over its earnings miss, as it reported $1.07 EPS compared to the consensus estimate of $1.19, which could lead to investor skepticism about its future performance.
	2025-01-16	+0.01 %
Incyte Corporation's stock (NASDAQ: INCY) experienced a slight increase of 0.01% after 180 Wealth Advisors LLC raised its holdings in the company by 3.9%, reflecting positive institutional interest and potential confidence from investors despite mixed earnings reports and ratings from research firms. Incyte Corporation's stock (NASDAQ: INCY) saw a slight increase of 0.01% following the news of significant institutional investments and positive analyst ratings, which reflect confidence in the company's growth potential in the biopharmaceutical sector. Incyte Corporation's stock (INCY) saw a slight increase of 0.01%, and analysts have issued a consensus recommendation of "Hold," with various price target adjustments affecting investor sentiment. The stock's rise can be attributed to recent positive adjustments in price targets from several analysts, indicating confidence in the company's future prospects despite a mixed earnings report.
	2025-01-13	+2.59 %
Incyte (INCY) stock increased by 2.59% following various analysts' upgrades and target price increases, signaling positive market sentiment despite missing earnings expectations, as multiple investment firms showed confidence in its future performance. Incyte (INCY) stock rose by 2.59% due to increased investor interest and attention within the biotech sector, driven by positive developments and news regarding key clinical candidates and partnerships among various biotech companies, which often create a favorable environment for related stocks.
	2025-01-10	-3.54 %
Incyte (INCY) stock fell by 3.54% following JPMorgan Chase & Co.'s significant reduction of its stake in the company by 42.3%, alongside various insider sales, which may have raised concerns among investors about the company's future performance and stability.
	2025-01-07	+1.78 %
Incyte Co. (NASDAQ: INCY) stock rose by 1.78% following the announcement of significant institutional investments, including a new position by CWA Asset Management Group, which bought nearly 28,000 shares, reflecting strong investor interest and confidence in the company. Incyte (INCY) stock rose by 1.78% possibly due to increased institutional interest, as several institutional investors have recently raised their stakes in the company, suggesting confidence in its future performance.
	2024-12-19	-0.73 %
Incyte Co. (INCY) stock fell by 0.73%, attributed to a disappointing quarterly earnings report that missed expectations, insider selling, and a general consensus rating of "Hold" among analysts.
	2024-12-16	+1.82 %
Incyte (NASDAQ: INCY) stock rose 1.82% following William Blair's reaffirmation of an "outperform" rating, alongside various other analysts maintaining or adjusting their ratings and price targets positively. Incyte (INCY) stock rose by 1.82% following several brokerage ratings adjustments, including a downgrade from a strong-buy to a buy rating by StockNews.com and other analysts reaffirming or adjusting their target prices for the stock. The increase in Incyte's stock may be attributed to positive revenue growth reported in its recent quarterly earnings, which exceeded consensus estimates, despite a miss in earnings per share. The article compares Can-Fite BioPharma and Merus as investment options, highlighting that Can-Fite has higher earnings and a more favorable analyst consensus despite lower revenue, which may indicate its recent stock price increase of 1.82% likely stems from investor confidence due to its promising clinical trials and potential for significant upside.
	2024-12-10	+0.51 %
Incyte Corporation's stock (INCY) rose by 0.51% due to recent analyst upgrades and institutional investor activity, despite a reported earnings miss and insider selling, along with a general positive trend in the biopharmaceutical sector.
	2024-12-05	+0.4 %
Incyte (INCY) stock saw a slight increase of 0.4% due to recent modifications in institutional holdings, with notable purchases from funds like Greenwood Capital Associates and SG Americas Securities, alongside positive analyst ratings that have increased price targets for the stock.
	2024-12-04	+3.6 %
Incyte (NASDAQ: INCY) stock rose by 3.6% due to increased institutional interest and positive analyst ratings, despite a recent decline in some hedge fund holdings. Incyte Co. (NASDAQ: INCY) saw a 3.6% increase in its stock price, attributed to a notable decrease in short interest, positive ratings adjustments from several analysts, and strong quarterly revenue growth compared to analysts' expectations.
	2024-12-03	-1.65 %
The article discusses the conditional approval of a combination therapy of fruquintinib and sintilimab for advanced endometrial cancer in China, marking a significant advancement in treatment options. The decline of Incyte (INCY) stock by 1.65% could be related to investor reactions to competitive developments in the oncology market, particularly the approval of new therapies like fruquintinib, which may affect the market dynamics and outlook for Incyte's products. Incyte (INCY) stock declined by 1.65% amid mixed news of institutional investors increasing their stakes and disappointing quarterly earnings, where the company reported earnings per share below estimates despite revenue growth. The decline in Incyte's stock price could be attributed to the disappointing earnings report, where the company missed consensus EPS estimates, indicating potential concerns about its financial performance and future profitability.
	2024-12-02	-1.81 %
Incyte (INCY) stock fell by 1.81% as BNP Paribas Financial Markets reduced its stake by 7.8% during the third quarter, reflecting potential investor concerns and insider selling.
	2024-11-29	-1.14 %
Incyte (INCY) stock fell by 1.14% following Citigroup's significant reduction of its holdings in the company by 42.8%, leading to concerns among investors regarding institutional confidence and potential volatility in the stock.
	2024-11-27	+0.87 %
Incyte (INCY) stock rose by 0.87% as it received a mix of analyst ratings, with some upgrades in price targets from firms like Goldman Sachs and Guggenheim, indicating bullish sentiment among investors despite a slight miss on recent earnings, which revealed strong revenue growth.
	2024-11-22	+1.89 %
Incyte (INCY) stock rose by 1.89% following positive analyst ratings and increased institutional interest, despite a recent earnings miss, reflecting market optimism about the company's future performance and ongoing developments in its biopharmaceutical ventures.
	2024-11-21	-0.93 %
Incyte (INCY) stock fell by 0.93% after analysts at Cantor Fitzgerald reaffirmed a "neutral" rating, and despite some upgrades from other analysts, concerns about the company's recent earnings report, which showed it missed EPS expectations, may have contributed to the decline.
	2024-11-19	-8.33 %
Incyte (INCY) stock dropped 8.33% after the company halted enrollment in a study of its drug INCB000262 due to toxicology issues and discontinued the development of another drug, raising concerns about future sales and clinical viability.
	2024-11-11	-2.22 %
Incyte (INCY) stock recently declined by 2.22%, likely due to a disappointing quarterly earnings report that missed analysts' expectations and indicated challenges in profitability despite revenue growth.
	2024-11-07	+1.72 %
Incyte (INCY) stock rose by 1.72% due to significant institutional investment activity, including a large acquisition by Pacer Advisors, suggesting strong interest and confidence in the company's growth potential despite recent earnings that fell slightly short of expectations.
	2024-11-06	+4.75 %
Incyte (INCY) stock rose by 4.75% due to strong investor interest in the biotech sector, particularly following positive developments and growth potential in their collaborations and product pipelines, including those with Agenus and other companies.
	2024-11-04	-0.5 %
Incyte (INCY) stock fell by 0.5% due to broader market declines influenced by global events and foreign fund outflows, causing investor sentiment to be weak. Incyte (INCY) stock dropped by 0.5% amid broader market declines influenced by global events and foreign fund outflows that affected investor sentiment.
	2024-11-01	+2.71 %
Incyte (INCY) stock increased by 2.71% following a report from Goldman Sachs that raised its price target from $63 to $70, indicating positive analyst sentiment despite a potential downside from its previous close.
	2024-10-30	+0.45 %
Incyte (INCY) stock rose by 0.45% following JPMorgan Chase & Co.'s decision to increase its price target on the shares from $65.00 to $71.00 while maintaining a "neutral" rating, indicating a positive outlook from analysts. Incyte Co. (NASDAQ: INCY) saw a 0.45% increase in its stock value, attributed to growing institutional investment and positive analyst upgrades, including a raised rating and price target by Bank of America and other firms, signaling stronger confidence in the company's prospects. Incyte Corporation's stock (NASDAQ:INCY) rose 0.45% following a strong third-quarter earnings report that showcased a 24% year-over-year revenue increase to $1.14 billion, surpassing analyst expectations, and positive performance from its key product, Jakafi. The stock likely went up due to the better-than-expected revenue results and continued growth in Jakafi's sales, indicating strong business performance and investor confidence. Incyte Co. (INCY) received an average "Hold" recommendation from twenty-one brokerages, which may have contributed to a modest 0.45% increase in its stock price due to steady market sentiment.
	2024-10-29	+12.04 %
Incyte (INCY) stock rose 12.0% despite reporting third-quarter profits below analysts' expectations because its revenue exceeded forecasts, driven by strong demand and sales for its key products, Jakafi and Opzelura. Incyte (INCY) stock increased by 12.04% following Bank of America's upgrade from a "neutral" to a "buy" rating and a price target increase from $68.00 to $90.00. Incyte (INCY) stock rose by 12.04% due to positive market sentiment and potential growth catalysts in the healthcare sector, particularly following strong earnings reports and developments in their product pipeline. Incyte (INCY) stock rose 12.04% last night, likely due to positive market trends and investor confidence in the pharmaceutical sector. Incyte (INCY) stock rose 12.04% after Forsta AP Fonden significantly increased its holdings in the company by 51.1%, indicating growing investor confidence in the biopharmaceutical firm's prospects.
	2024-10-25	-0.26 %
Incyte (INCY) stock declined by 0.26% after Dumont & Blake Investment Advisors LLC reported a 49.7% reduction in its stake in the biopharmaceutical company during the third quarter. The article discusses a study from Johns Hopkins Kimmel Cancer Center that identifies a new stage of tertiary lymphoid structures in liver tumors, which may be crucial for improving immunotherapy outcomes for hepatocellular carcinoma patients. The Incyte (INCY) stock may have declined by -0.26% due to investor reactions to broader market conditions or uncertainties regarding the company's own developments in cancer therapies, especially in light of the study's focus on competing immunotherapy research.

1
500 / page